HomeWebinarsRight First Time: Manufacturing Platform Development for Viral Vectors

Right First Time: Manufacturing Platform Development for Viral Vectors


In this webinar, you will learn:

  • Suspension-based upstream viral vector platforms
  • Analytical testing strategies for viral vector production
  • Final filtration and cost-modeling for viral vectors

Detailed description:

Platform production processes simplify process development and make it easier to scale-up effectively. Similarly, a platform analytical testing strategy reduces the time for assay development. We describe key considerations when building such an integrated platform for viral vectors, and propose near-term and future-state solutions.


David Loong, Ph.D


Merck Associate Director, Novel Modalities

David Loong is the Associate Director, Novel Modalities APAC, Strategy Ops. Previously, David held roles as a senior Scientist in Biotech startups encompassing cell & gene therapy process development services, mAb discovery, and preclinical development. He also has an extensive track record providing contract research services as a Senior Research Scientist at AMRI Global, and as a product custodian for API GMP manufacturing at GSK. He holds a Ph.D. in Synthetic Organic Chemistry from the Australian National University and a BTech(Hons) from Massey University (NZ) specializing in chemistry and process engineering.

Webinar Information

Pharmaceutical and biopharmaceutical manufacturing

  • Classical pharma manufacturing
  • Duration:1 hour

  • Language:English

  • Session 1:Tue, April 20, 2021
    02:00 AM PST